A study protocol for an observational cohort investigating cardiac transthyretin amyloidosis flow reserve before and after Tafamidis treatment: The AMYTRE study

Bastien Vançon, Arnaud Bisson, Maxime Courtehoux, Anne Bernard, Matthieu Bailly, Bastien Vançon, Arnaud Bisson, Maxime Courtehoux, Anne Bernard, Matthieu Bailly

Abstract

Introduction: Anginal symptoms and signs of ischemia have been reported in some patients with cardiac transthyretin amyloidosis (ATTR) without obstructive epicardial coronary artery disease (CAD). Few studies found that coronary microvascular dysfunction was highly prevalent in subjects with cardiac amyloidosis, even in the absence of epicardial CAD. The purpose of this study is to confirm the coronary microvascular dysfunction, and to go further with evaluation of the effect of Tafamidis on microvascular dysfunction after 24 months of treatment.

Methods and analysis: This study is a multicentric, prospective, observational cohort study. Adult patients with confirmed ATTR cardiomyopathy seen in the nuclear medicine departments of three large referral centers and treated with Tafamidis will be included. At baseline, patients will have a clinical and echocardiography evaluation. They will undergo a dynamic rest/stress cardiac scintigraphy with flow and reserve measurements before and 24 months after Tafamidis introduction. The primary outcome of this study will be the variation of stress and rest myocardial blood flow and flow reserve between baseline and 24 months after treatment. The effect of Tafamidis will be assessed by an intention to treat analysis.

Ethics and dissemination: The study has received the following approvals: Orleans Hospital Research Committee (CHRO-2021-05) and Sud-Mediterranée IV Regional Ethics Committee (21 06 02). Results will be made available to physicians, the funders, and other researchers.

Clinical trial registration: [https://ichgcp.net/clinical-trials-registry/NCT05103943], identifier [NCT05103943].

Keywords: CZT SPECT; Tafamidis; amyloidosis; myocardial blood flow; myocardial flow reserve.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Vançon, Bisson, Courtehoux, Bernard and Bailly.

Figures

FIGURE 1
FIGURE 1
Flow of the participants throughout the study. MBF, Myocardial Blood Flow; MFR, Myocardial Flow Reserve.
FIGURE 2
FIGURE 2
Dynamic scintigraphy protocol.

References

    1. Al Suwaidi J, Velianou JL, Gertz MA, Cannon RO, III, Higano ST, Holmes DR, Jr., et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. (1999) 131:838–41. 10.7326/0003-4819-131-11-199912070-00007
    1. Ogawa H, Mizuno Y, Ohkawara S, Tsujita K, Ando Y, Yoshinaga M, et al. Cardiac amyloidosis presenting as microvascular angina–a case report. Angiology. (2001) 52:273–8. 10.1177/000331970105200407
    1. Whitaker DC, Tungekar MF, Dussek JE. Angina with a normal coronary angiogram caused by amyloidosis. Heart. (2004) 90:e54. 10.1136/hrt.2004.038984
    1. Dorbala S, Vangala D, Bruyere J, Jr., Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. (2014) 2:358–67. 10.1016/j.jchf.2014.03.009
    1. Nam MC, Nel K, Senior R, Greaves K. Abnormal myocardial blood flow reserve observed in cardiac amyloidosis. J Cardiovasc Ultrasound. (2016) 24:64–7. 10.4250/jcu.2016.24.1.64
    1. Bocher M, Blevis IM, Tsukerman L, Shrem Y, Kovalski G, Volokh L. A fast cardiac gamma camera with dynamic SPECT capabilities: Design, system validation and future potential. Eur J Nucl Med Mol Imaging. (2010) 37:1887–902. 10.1007/s00259-010-1488-z
    1. Wells RG, Timmins R, Klein R, Lockwood J, Marvin B, deKemp RA, et al. Dynamic SPECT measurement of absolute myocardial blood flow in a porcine model. J Nucl Med. (2014) 55:1685–91. 10.2967/jnumed.114.139782
    1. Agostini D, Roule V, Nganoa C, Roth N, Baavour R, Parienti JJ, et al. First validation of myocardial flow reserve assessed by dynamic 99m Tc-sestamibi CZT-SPECT camera: Head to head comparison with 15 O-water PET and fractional flow reserve in patients with suspected coronary artery disease. The WATERDAY study. Eur J Nucl Med Mol Imaging. (2018) 45:1079–90. 10.1007/s00259-018-3958-7
    1. de Souza A, Goncalves BKD, Tedeschi AL, Lima RSL. Quantification of myocardial flow reserve using a gamma camera with solid-state cadmium-zinc-telluride detectors: Relation to angiographic coronary artery disease. J Nucl Cardiol. (2019) 28:876–84. 10.1007/s12350-019-01775-z
    1. Giubbini R, Bertoli M, Durmo R, Bonacina M, Peli A, Faggiano I, et al. Comparison between N(13)NH3-PET and (99m)Tc-Tetrofosmin-CZT SPECT in the evaluation of absolute myocardial blood flow and flow reserve. J Nucl Cardiol. (2019) 28:1906–18. 10.1007/s12350-019-01939-x
    1. Bailly M, Ribeiro MJ, Angoulvant D. Combining flow and reserve measurement during myocardial perfusion imaging: A new era for myocardial perfusion scintigraphy? Arch Cardiovasc Dis. (2021) 114:818–27. 10.1016/j.acvd.2021.10.006
    1. Driessen RS, Danad I, Stuijfzand WJ, Raijmakers PG, Schumacher SP, van Diemen PA, et al. Comparison of coronary computed tomography angiography, fractional flow reserve, and perfusion imaging for ischemia diagnosis. J Am Coll Cardiol. (2019) 73:161–73. 10.1016/j.jacc.2018.10.056
    1. Lee JS, Kovalski G, Sharir T, Lee DS. Advances in imaging instrumentation for nuclear cardiology. J Nucl Cardiol. (2019) 26:543–56. 10.1007/s12350-017-0979-8
    1. Klein R, Celiker-Guler E, Rotstein BH, deKemp RA. PET and SPECT tracers for myocardial perfusion imaging. Semin Nucl Med. (2020) 50:208–18. 10.1053/j.semnuclmed.2020.02.016
    1. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. (2018) 379:1007–16. 10.1056/NEJMoa1805689
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. (2021) 42:3599–726. 10.1093/eurheartj/ehab368
    1. Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. (2019) 139:431–43. 10.1161/CIRCULATIONAHA.118.035831
    1. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. (2018) 379:22–31. 10.1056/NEJMoa1716793
    1. Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: An update on diagnosis and treatment. ESC Heart Fail. (2019) 6:1128–39. 10.1002/ehf2.12518
    1. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. (2005) 46:1076–84. 10.1016/j.jacc.2005.05.073
    1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. (2019) 25:e1–39. 10.1016/j.cardfail.2019.08.001
    1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. (2016) 133:2404–12. 10.1161/CIRCULATIONAHA.116.021612
    1. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-diagnostic criteria and appropriate utilization. J Card Fail. (2019) 25:854–65. 10.1016/j.cardfail.2019.08.002
    1. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med. (2011) 3:87s24. 10.1126/scitranslmed.3001628
    1. Aikawa T, Naya M, Obara M, Manabe O, Magota K, Koyanagawa K, et al. Effects of coronary revascularization on global coronary flow reserve in stable coronary artery disease. Cardiovasc Res. (2019) 115:119–29. 10.1093/cvr/cvy169
    1. Choi WG, Kim GC, Lee CH, Kim HY, Kim DW. The effect of antiplatelet drug on coronary endothelial and microvascular function: Comparison with ticagrelor and clopidogrel. Korean J Intern Med. (2021) 36:352–61. 10.3904/kjim.2019.293
    1. Jeong YJ, Park K, Kim YD. Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography. Am Heart J. (2020) 222:121–30. 10.1016/j.ahj.2020.01.013
    1. Murthy VL, Naya M, Foster CR, Gaber M, Hainer J, Klein J, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation. (2012) 126:1858–68. 10.1161/CIRCULATIONAHA.112.120402
    1. Potier L, Chequer R, Roussel R, Mohammedi K, Sismail S, Hartemann A, et al. Relationship between cardiac microvascular dysfunction measured with 82Rubidium-PET and albuminuria in patients with diabetes mellitus. Cardiovasc Diabetol. (2018) 17:11. 10.1186/s12933-017-0652-1
    1. Rimoldi O, Maranta F. Microvascular dysfunction in infiltrative cardiomyopathies. J Nucl Cardiol. (2019) 26:200–7. 10.1007/s12350-017-0991-z
    1. Monteiro C, Mesgazardeh JS, Anselmo J, Fernandes J, Novais M, Rodrigues C, et al. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight. (2019) 4:e126526. 10.1172/jci.insight.126526
    1. Falk RH, Haddad M, Walker CR, Dorbala S, Cuddy SAM. Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol. (2021) 3:580–6. 10.1016/j.jaccao.2021.08.007

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren